UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R

PloS one, 2012-10, Vol.7 (10), p.e47053

2012

Volltextzugriff (PDF)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer

Cell death & disease, 2021-07, Vol.12 (7), p.684-684, Article 684

2021

Volltextzugriff (PDF)

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

International journal of cancer, 2014-10, Vol.135 (8), p.1961-1969

2014

Volltextzugriff (PDF)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis

Journal of hematology and oncology, 2022-06, Vol.15 (1), p.72-72, Article 72

2022

Volltextzugriff (PDF)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer

BMC cancer, 2018-04, Vol.18 (1), p.446-446, Article 446

2018

Volltextzugriff (PDF)

Multi-Channel Based on Attention Network for Infrared Small Target Detection

Shanghai jiao tong da xue xue bao, 2024, Vol.29 (3), p.414-427

2024

Volltextzugriff (PDF)

Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

Breast cancer research : BCR, 2022-08, Vol.24 (1), p.1-57, Article 57

2022

Volltextzugriff (PDF)

Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study

Supportive care in cancer, 2020-08, Vol.28 (8), p.3819-3829

2020

Volltextzugriff (PDF)

Clinical Study of the Necessity of Replanning Before the 25th Fraction During the Course of Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma

International journal of radiation oncology, biology, physics, 2010-06, Vol.77 (2), p.617-621

2010

Volltextzugriff (PDF)

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Nature communications, 2022-07, Vol.13 (1), p.4025-4025, Article 4025

2022

Volltextzugriff (PDF)

Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest

Breast cancer research and treatment, 2022-02, Vol.192 (1), p.75-87

2022

Volltextzugriff (PDF)

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer

Frontiers in immunology, 2022-11, Vol.13, p.1056932-1056932

2022

Volltextzugriff (PDF)

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial

Investigational new drugs, 2022-04, Vol.40 (2), p.330-339

2022

Volltextzugriff (PDF)

The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway

Frontiers in pharmacology, 2023-01, Vol.13, p.1081978-1081978

2023

Volltextzugriff (PDF)

A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211022890-17588359211022890

2021

Volltextzugriff (PDF)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

BMC cancer, 2011-06, Vol.11 (1), p.248-248, Article 248

2011

Volltextzugriff (PDF)

Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231217972-17588359231217972

2023

Volltextzugriff (PDF)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Frontiers in oncology, 2021-04, Vol.11, p.664429-664429

2021

Volltextzugriff (PDF)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

Frontiers in endocrinology (Lausanne), 2023-10, Vol.14, p.1270453-1270453

2023

Volltextzugriff (PDF)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis

Frontiers in endocrinology (Lausanne), 2023-12, Vol.14, p.1325540-1325540

2023

Volltextzugriff (PDF)

Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

Investigational new drugs, 2020-04, Vol.38 (2), p.507-514

2020

Volltextzugriff (PDF)

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

Journal of translational medicine, 2023-06, Vol.21 (1), p.360-360, Article 360

2023

Volltextzugriff (PDF)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis

Cancer Research and Treatment, 2020, 52(4), , pp.1059-1066

2020

Volltextzugriff (PDF)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

Frontiers in oncology, 2022-08, Vol.12, p.837963-837963

2022

Volltextzugriff (PDF)

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study

Frontiers in oncology, 2022-03, Vol.12, p.775081-775081

2022

Volltextzugriff (PDF)

1 – 25 von 751

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(663)
Mit Volltextzugriff
(658)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(26)
Cancer Research
(14)
Ssrn Electronic Journal
(12)
Bmc Cancer
(11)
Frontiers In Oncology
(11)
Oncotarget
(10)
Scientific Reports
(10)
Cancer Medicine
(9)
Breast Cancer Research And Treatment
(7)
Atmosphere
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer

Multi-Channel Based on Attention Network for Infrared Small Target Detection

Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study

Clinical Study of the Necessity of Replanning Before the 25th Fraction During the Course of Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial

The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway

A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis

Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study

Suchergebnisse filtern